Replies to post #135340 on Biotech Values

[DewDiligence]

BMY off 3%, AZN off 2% on dapagliflozin CRL. For BMY, which has had a lot of pipeline success (e.g. Yervoy, Eliquis) in the past year, today’s drop seems a bit overdone.